293 related articles for article (PubMed ID: 24415864)
1. Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors.
Li TT; Qiu F; Qian ZR; Wan J; Qi XK; Wu BY
World J Gastroenterol; 2014 Jan; 20(1):118-25. PubMed ID: 24415864
[TBL] [Abstract][Full Text] [Related]
2. Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors.
Lloyd KA; Parsons BN; Burkitt MD; Moore AR; Papoutsopoulou S; Boyce M; Duckworth CA; Exarchou K; Howes N; Rainbow L; Fang Y; Oxvig C; Dodd S; Varro A; Hall N; Pritchard DM
Cell Mol Gastroenterol Hepatol; 2020; 10(1):113-132. PubMed ID: 32004755
[TBL] [Abstract][Full Text] [Related]
3. The Morphologic Spectrum of Gastric Type 1 Enterochromaffin-Like Cell Neuroendocrine Tumors.
Poveda JC; Chahar S; Garcia-Buitrago MT; Montgomery EA; McDonald OG
Mod Pathol; 2023 Apr; 36(4):100098. PubMed ID: 36913909
[TBL] [Abstract][Full Text] [Related]
4. Enterochromaffin-like Cell Hyperplasia-Associated Gastric Neuroendocrine Tumors May Arise in the Setting of Proton Pump Inhibitor Use.
Rais R; Trikalinos NA; Liu J; Chatterjee D
Arch Pathol Lab Med; 2022 Mar; 146(3):366-371. PubMed ID: 34283890
[TBL] [Abstract][Full Text] [Related]
5. Gastric neuroendocrine tumors.
Delle Fave G; Capurso G; Annibale B; Panzuto F
Neuroendocrinology; 2004; 80 Suppl 1():16-9. PubMed ID: 15477710
[TBL] [Abstract][Full Text] [Related]
6. [Gastric neuroendocrine tumors].
Alekberzade AV; Krylov NN; Lipnitskiy EM; Shakhbazov RO; Azari F
Khirurgiia (Mosk); 2019; (12):111-120. PubMed ID: 31825351
[TBL] [Abstract][Full Text] [Related]
7. Surgical indication of type I gastric neuroendocrine tumors.
Ruiz Pardo J; Sánchez Fuentes PA; Vidaña Márquez E; García-Redondo M; González Sánchez D; Belda Lozano R; Ferrer-Márquez M; Reina Duarte Á
Rev Esp Enferm Dig; 2024 May; 116(5):280-282. PubMed ID: 37170558
[TBL] [Abstract][Full Text] [Related]
8. CEA Level, Radical Surgery, CD56 and CgA Expression Are Prognostic Factors for Patients With Locoregional Gastrin-Independent GNET.
Li Y; Bi X; Zhao J; Huang Z; Zhou J; Li Z; Zhang Y; Li M; Chen X; Hu X; Chi Y; Zhao D; Zhao H; Cai J
Medicine (Baltimore); 2016 May; 95(18):e3567. PubMed ID: 27149478
[TBL] [Abstract][Full Text] [Related]
9. Gastric neuroendocrine neoplasms.
Lamberti G; Panzuto F; Pavel M; O'Toole D; Ambrosini V; Falconi M; Garcia-Carbonero R; Riechelmann RP; Rindi G; Campana D
Nat Rev Dis Primers; 2024 Apr; 10(1):25. PubMed ID: 38605021
[TBL] [Abstract][Full Text] [Related]
10. Endoscopic diagnosis and management of type I neuroendocrine tumors.
Sato Y
World J Gastrointest Endosc; 2015 Apr; 7(4):346-53. PubMed ID: 25901213
[TBL] [Abstract][Full Text] [Related]
11. A 15-year experience with gastric neuroendocrine tumors: Does type make a difference?
Postlewait LM; Baptiste GG; Ethun CG; Le N; Cardona K; Russell MC; Willingham FF; Kooby DA; Staley CA; Maithel SK
J Surg Oncol; 2016 Oct; 114(5):576-580. PubMed ID: 27393718
[TBL] [Abstract][Full Text] [Related]
12. Defining prognostic parameters of well-differentiated gastric neuroendocrine tumors based on metastatic potential: a two-center experience.
Kurtulan O; Turhan N; Gedikoğlu G; Akyol A; Sökmensüer C
Acta Gastroenterol Belg; 2022; 85(2):339-345. PubMed ID: 35709778
[TBL] [Abstract][Full Text] [Related]
13. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
14. [Subtype classification and clinicopathological characteristics of gastric neuroendocrine neoplasms: an analysis of 241 cases].
Zhang P; Zhang Y; Zhang C; Shi Y; Liu J; Liu Q; Yu L; Wang M; Zou G; Lou J; Chen J; Tan H
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1241-1246. PubMed ID: 27928793
[TBL] [Abstract][Full Text] [Related]
15. A clinical perspective on gastric neuroendocrine neoplasia.
Lawrence B; Kidd M; Svejda B; Modlin I
Curr Gastroenterol Rep; 2011 Feb; 13(1):101-9. PubMed ID: 21080245
[TBL] [Abstract][Full Text] [Related]
16. A cumulative effect involving malfunction of the PTH1R and ATP4A genes explains a familial gastric neuroendocrine tumor with hypothyroidism and arthritis.
Calvete O; Herraiz M; Reyes J; Patiño A; Benitez J
Gastric Cancer; 2017 Nov; 20(6):998-1003. PubMed ID: 28474257
[TBL] [Abstract][Full Text] [Related]
17. Recurrent gastric neuroendocrine tumors treated with total gastrectomy.
Jung M; Kim JW; Jang JY; Chang YW; Park SH; Kim YH; Kim YW
World J Gastroenterol; 2015 Dec; 21(46):13195-200. PubMed ID: 26675502
[TBL] [Abstract][Full Text] [Related]
18. Multifocal G1-G2 gastric neuroendocrine tumors: Differentiating between Type I, II and III, a clinicopathologic review.
Algashaamy K; Garcia-Buitrago M
World J Clin Cases; 2019 Sep; 7(17):2413-2419. PubMed ID: 31559277
[TBL] [Abstract][Full Text] [Related]
19. Gastric neuroendocrine tumors in our institutions according to the WHO 2010 classification.
Endo S; Dousei T; Yoshikawa Y; Hatanaka N; Taniyama K; Yamauchi A; Kamiike W; Nishijima J
Int Surg; 2012; 97(4):335-9. PubMed ID: 23294075
[TBL] [Abstract][Full Text] [Related]
20. [Neuroendocrine tumors of the stomach. Pathogenesis, classification and clinical aspects].
Bordi C; Azzoni C; D'Adda T; Caruana P; Carlinfante G
Pathologe; 1997 Jul; 18(4):313-21. PubMed ID: 9380606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
